As­traZeneca and Sanofi tout break­through in €645M al­liance against lead­ing cause of in­fant death

Af­ter 23 years, a new treat­ment for one of the lead­ing caus­es of in­fant death may be on the hori­zon.

As­traZeneca and Sanofi an­nounced Mon­day that an ex­per­i­men­tal an­ti­body, nir­se­vimab, suc­cess­ful­ly pre­vent­ed in­fants from de­vel­op­ing RSV in­fec­tions that re­quired any type of med­ical at­ten­tion. The two Big Phar­mas of­fered few de­tails about the large Phase III tri­al, but said the re­sults came soon­er than ex­pect­ed and that they would file for ap­provals around the globe next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER